Lead mAb (name not specified)
COVID-19 (Prevention/Treatment)
Approved (EUA)Received U.S. FDA Emergency Use Authorization
Key Facts
Indication
COVID-19 (Prevention/Treatment)
Phase
Approved (EUA)
Status
Received U.S. FDA Emergency Use Authorization
Company
About Invivyd
Invivyd is on a mission to rapidly and continually deliver antibody-based therapies that keep pace with evolving viral threats, starting with COVID-19. The company employs a unique, integrated technology platform to develop best-in-class antibodies that are more potent and resistant to virus evolution than the natural immune response. Its strategic focus includes building a robust pipeline for prevention and treatment, with a lead asset authorized for emergency use and a Phase 3 candidate showing positive results. The leadership team comprises seasoned executives with deep experience in infectious disease drug development and commercialization.
View full company profile